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Background: Corticosteroids are a potent group of medicines, with many adverse effects, that are widely
prescribed in palliative care for both specific and non-specific indications. The aim of this study was to document
current patterns of corticosteroid prescribing in New Zealand palliative care settings and to reflect on whether they
were in line with international experience.
Methods: A retrospective review of inpatient use of corticosteroids was undertaken in a sample of six New Zealand
hospices. Data were collected on numbers of patients prescribed corticosteroids, indications for use, choice of
agent, doses and dosage changes, duration of course, incidence of adverse effects, method of stopping, use of
guidelines, and processes for monitoring and review.
Results: The case notes of 1179 inpatients were reviewed and 768 patients (65.1%) had received at least one
course of corticosteroids. There was a marked consistency in the proportion of patients prescribed corticosteroids
among the sample hospices (61-69%). Detailed information was recorded for a sample of 260 patients.
Corticosteroids were prescribed most commonly for non-specific reasons (40.4% of prescribing events), followed by
neurological (25.3%) and soft tissue infiltration symptoms (14.4%). The agent of choice was dexamethasone with
a dose range of 1 mg to 40 mg and a median dose of 8 mg. The median course duration for all corticosteroid
prescribing events was 29 days. Abrupt stopping occurred in 72 (23.2%) cases, of these 35 (49%) had been on a
course of corticosteroids for more than three weeks. Guidelines were only available in one hospice. Monitoring and
review was documented in 135 (52%) of cases, and adverse effects were recorded in 82 (32%); these are likely to be
underestimates due to a high level of non-recording.
Conclusions: This New Zealand study showed that corticosteroids are widely prescribed in palliative care, most
commonly for non-specific indications. These findings are consistent with the international literature in this area
and this large, multi-site study adds weight to the findings and the need for ongoing discussion about the place of
these drugs in palliative care.
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Corticosteroids can be considered to be ‘old’ medicines;
their prescribing in palliative therapy has been common-
place since the late 1950s [1-3]. They are commonly
prescribed for patients in palliative care for both specific
and non-specific indications [4-9]. Corticosteroids are
potent medicines with frequent adverse effects and while
the intent is to achieve beneficial results for the patient,
the consequences of long-term use may counteract this* Correspondence: j.shaw@auckland.ac.nz
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distribution, and reproduction in any mediumobjective [10]. There have been few randomised controlled
trials of corticosteroids in palliative care [7,11-13], and
caution has been voiced about their haphazard use [14].
Corticosteroid use short-term for specific reasons, such as
neurological (spinal cord compression) or soft tissue infil-
tration (e.g. by abdominal tumours), is supported by weak
evidence [7,15].
Concerns have been expressed about the non-specific
use of corticosteroids, the most common indication for
their prescribing, since there appears to be little robust
evidence to support this practice [5]. Some authors have
observed that the use of corticosteroids for ‘non-specific’entral Ltd. This is an Open Access article distributed under the terms of the
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ness of breath or poor wellbeing) had some positive short-
term results, but this benefit seldom lasted more than four
weeks [14]. Several studies reported a significant improve-
ment in appetite and strength after two weeks of dexa-
methasone, but declining effects after four weeks [16,17].
Some caution has to be exercised in interpretation of the
literature as there are differences in terminology with re-
spect to both palliative care patients (some corticosteroid
studies relate only to ‘advanced cancer’ or ‘pre-terminal’
cancer) and to the categorisation of corticosteroid indica-
tions, particularly the definition of ‘non-specific’ symp-
toms. Some authors restrict the definition of non-specific
to anorexia-cachexia symptoms (anorexia, fatigue, weight
loss), while most have included more general symptoms
such as breathlessness, nausea and pain. Pain, of course,
could also be attributable to specific causes. The broader
definition of non-specific is used in this paper.
Twycross [18] advocated the use of a clear plan when
corticosteroids were being administered, including regular
monitoring leading to dose adjustment, and prescribing
for the shortest time frame at the lowest effective dose
[18]. Other authors recommended that if corticosteroids
were of no benefit then they should be discontinued
[6,10]. Lundstrom et al. [19] argued that the benefits of
high-dose corticosteroids in the dying patient, while con-
troversial, may have a profound effect on end of life symp-
toms and perceptions of both patients and families in
terms of hope and psychological well-being, even if short-
term. They commented that “reduced symptoms contrib-
ute to feelings of normalising life, symbolising hope” [19].
The main synthetic corticosteroids used in palliative care
are prednisone, dexamethasone, methylprednisolone and
betamethasone [5,20-22]. Based on their chemical struc-
tures [23], some corticosteroids have stronger glucocortic-
oid properties which confer greater anti-inflammatory
effects, but also a greater likelihood of adverse effects [24].
The long-term administration of glucocorticoids can lead
to Cushing’s syndrome [25,26], the consequences of which
can be of such significance with respect to changes in
physical appearance and emotional state that some patients
and families consider the effects of long-term corticoste-
roids to be worse than the original indication [14,27-29].
All four agents have long biological half-lives, particu-
larly dexamethasone and betamethasone [24]; they can
therefore be given as a once daily dose, early in the day
[30-32]. Internationally, the corticosteroid of choice ap-
pears to be dexamethasone [11,14,20,33-38], which, with
betamethasone, has the highest anti-inflammatory proper-
ties [24]. Reasons for its choice may include the availability
of oral and parenteral formulations, lower cost, longer
duration of action, lack of mineralocorticoid effects and
higher glucocorticoid activity leading to an enhanced anti-
inflammatory effect [20,24]. Many studies have found thata high proportion of patients in a palliative care service
(32-80%) will receive at least one course of corticosteroids
[4,6,8,14,28,34,35,39-42]. The literature is also consistent
that 50% to 70% of patients prescribed corticosteroids for
more than three weeks will have adverse effects [3,4,14].
These effects are not always recognised as being cortico-
steroid in origin and may be wrongly assumed to be part
of the dying process [16].
Shafford [14] advocated the development of guidelines
to curb the potential for haphazard prescribing [14].
Guidelines need to be evidence-based to ensure the best
outcome for the patient with minimum adverse effects,
as well as being easy to follow, clinically relevant, com-
prehensive, and flexible for busy clinicians [5]. A number
of studies and guidelines advise that if corticosteroids
show no benefit they should be stopped before adverse
effects occur [6,10,18,42-44], but a course taken for longer
than three weeks (some guidelines suggest two weeks)
should be reduced gradually and not stopped abruptly
[14]. Abrupt cessation may lead to adrenal suppression
and an increase in terminal restlessness [25,43,45-47].
Given the challenges associated with the prescribing of
these agents in palliative care patients, and evidence in
the literature of sub-optimal practice, it was considered
timely to undertake a review of their prescribing in a New
Zealand context. The aim of this study was to document
current patterns of corticosteroid prescribing in a sample
of New Zealand palliative care settings and to reflect on
whether it is in line with international experience.
Methods
This study was approved by the New Zealand Multi-
regional Ethics committee (MEC/08/37/EXP). It was
accomplished by undertaking a retrospective review of
corticosteroid prescribing in a sample of New Zealand
hospices over a defined period (January 1st to December
31st 2007). The study was the first phase of a larger
study investigating influences on the prescribing of cor-
ticosteroids in the palliative care setting. The second
phase which investigated clinicians’ perspectives on cor-
ticosteroid prescribing has been reported elsewhere.
Study sites
In 2007, there were 32 hospices throughout New Zealand.
A purposive sample of six hospices (approximately one in
five) was considered sufficient to give an accurate ‘snap-
shot’ of corticosteroid prescribing at the time. Characteris-
tics of the sample hospices are shown in Table 1. The
rationale was to have a balance of larger urban and smaller
rural hospices, thus gaining a cross-section of corticoster-
oid prescribing nationally. The invitation to be part of this
review was accepted by the hospice managers and medical
directors. Each hospice was assigned a code number from
one to six for confidentiality purposes. Individual patient
Table 1 Characteristics of sample hospices
Location Population base Number
of beds
Hospice 1: Urban 295,000 18
Hospice 2: Urban with large rural
catchment
180,000 12
Hospice 3: Urban 102,000 10
Hospice 4: Urban with rural catchment 60,000 5
Hospice 5: Urban with large rural
catchment
104,000 6
Hospice 6: Metropolitan 426,000
(not sole provider)
9
Table 2 Corticosteroid prescribing and review database
Corticosteroid prescribing and review database
1 Hospice code
2 Individual patient code
3 Patient history: gastrointestinal tract cancer; urogenital cancer; lung
cancer; breast cancer; melanoma; haematological cancers; brain
cancer; other cancers; non-cancer
4 Patient age (years)
5 Patient gender
6 Corticosteroid prescribing event: which agent was prescribed?
(separate entry for each prescribing event)
7 Date, if noted, when the corticosteroid was commenced
8 Initial dose of corticosteroid prescribed
9 Route: oral, subcutaneous; intramuscular; intravenous
10 Prescribed by: hospital doctor; general practitioner; hospice doctor
11 Indication (reason) for corticosteroid prescribing (see Table 3)
12 Concurrent prescribing of: omeprazole; NSAID; phenytoin; zopiclone
13 Corticosteroid stopped: gradually; abruptly; patient died while still
on their corticosteroid
14 Adverse effects to corticosteroids: yes; no; not recorded
15 Was drug reviewed?
16 Date of review
17 Was there an indication change for giving corticosteroid: if yes,
complete a new entry
18 Dose change decision: decrease dose; increase dose; stop
corticosteroid; no change; change corticosteroid: if yes, complete
a new entry
19 Reason for change: patient deterioration; no change in patient;
improvement in patient; not recorded
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anonymous (all patients had died by the time the review
was undertaken).
Sample size
A pilot study was performed at the researcher’s (AD)
home hospice to estimate the proportion (%) of inpa-
tients likely to be prescribed corticosteroids. This hos-
pice was not included in the study sample because of
the close working relationship with the author. Of 250
inpatients at this hospice, 49% had been prescribed
corticosteroids. Using this information, a sample of ap-
proximately 1250 inpatients was considered sufficient to
enable estimation of the true proportion of palliative
care patients prescribed corticosteroids throughout New
Zealand, with a 95% confidence level of ± 2.8%. For the
patients prescribed corticosteroids whose records were
examined, a sample size of 210 was considered sufficient
to enable an estimation of a true proportion of patients
with a drug review, with a 95% confidence interval of
6.1%. The author (AD) initially reviewed 1179 individual
inpatients’ case notes from the six hospices for the 2007
calendar year and separated out the notes for all those
who had been prescribed at least one course of cortico-
steroids. For the 768 patients who had been prescribed
corticosteroids, every third set of notes was selected for
review and corticosteroid prescribing details were en-
tered into a database to allow further analysis.
Data collection
Data were collected between February and December
2009 from the 2007 inpatient case notes of those pa-
tients prescribed corticosteroids selected as part of the
study sample. Data on survival times beyond 2007 were
not recorded, but by the time the case notes were
reviewed in 2009, all patients in the sample had died (it
was an Ethics requirement that only deceased patients’
notes could be accessed). The database recorded patient
demographics and confirmed diagnoses, as well as de-
tails of each corticosteroid prescribing event and cortico-
steroid review (Table 2).If a patient was prescribed a different corticosteroid as
the result of a drug review, or if a corticosteroid was
prescribed for a new indication, this was recorded as a
separate prescribing event. The sample included both pa-
tients who continued a course of corticosteroids started
before admission and those who commenced corticoste-
roids after admission. Multiple re-admissions were com-
mon; these were identified through the case notes and
patients retained the original research code allocated to
them. If the patient was still on a course of corticosteroids
from a previous admission, this was recorded as a con-
tinuation event; if a new course was prescribed, this was
recorded as a separate prescribing event.
Eight indications were selected for this study (Table 3).
While some of these are not mutually exclusive (e.g. soft
tissue infiltration can include capsular stretching by liver
metastases and so on) and the definition of non-specific
is open to interpretation, the indications listed were similar
to those used in a number of previous studies so as to
allow useful comparisons. The category of not clear/other
was only used when there was an indication which could
not be otherwise classified, or where there was insufficient
information concerning the indication in the patient notes.
Stopping abruptly was defined as the patient being on a
Table 3 Description of indications
1 Non-specific: to include lack of appetite, wellbeing, fatigue nausea,
vomiting, pain and shortness of breath
2 Neurological to include: raised intracranial pressure, cerebral
tumours, spinal cord compression and nerve compression
or infiltration
3 Capsular stretching: to include liver metastases and other visceral
organ metastases
4 Soft tissue infiltration: to include head and neck tumours and
abdominal and pelvic tumours
5 Tenesmus: rectal pain due to invasive tumours
6 Inflammation with syringe driver sites (subcutaneous route)
7 Not clear/other: to include any indication, which was either
not clear or did not fit in the other categories
8 Chemotherapy
Table 4 Patients prescribed corticosteroids in the sample
hospices
Facility Number (%) of patients at
each hospice prescribed at
















1179 768 Mean (s.d.): 65.1% (3.3%)
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defined as being performed if it was recorded in the patient
notes; and adverse effects were defined as those listed as
corticosteroid-specific in standard pharmacology texts,
notably the appearance of Cushingoid features [23-26].
Data analysis
Data are presented as descriptive statistics and frequen-
cies with 95% confidence intervals, means and standard
deviations (s.d.), medians and interquartile ranges (IQR)
were used as appropriate to describe the characteristics
of the patients and their treatments. Chi-square tests
were performed to test for differences in the proportions
of patients receiving particular treatments between hos-
pices. Only those situations where a statistically significant
result was found are reported. The clustering of data
where patients had a number of dose changes within one
corticosteroid prescribing event was allowed for in the
analyses and calculation of confidence intervals. SAS ver-
sion 9.12 was used in the analyses of the data. As the hos-
pices were not randomly selected, they were included as
fixed factors in the analyses.
Results
At the time of this retrospective review, 1179 inpatient
notes were reviewed. As shown in Table 4, at least one
course of corticosteroids was prescribed for 768 of these
patients. There was a marked consistency in the propor-
tion of patients prescribed corticosteroids across the six
hospices, ranging from 61% to 69% with a mean of
65.1% (s.d. 3.3%); these differences were not significant
(p = 0.366). Of the 768 patients prescribed corticosteroids,
one in three (260) were selected for detailed analysis. For
the 260 patients reviewed, there were 312 corticosteroid
prescribing events recorded during the study period. As
would be anticipated, there were numerous dose changes
and some route changes during a single course of cortico-
steroids. There were 891 such changes documented in thepatient notes; however, this is likely to be an underesti-
mate as it was very difficult to track this information in a
number of cases.
The demographic characteristics of those patients pre-
scribed corticosteroids whose case notes were reviewed
(260) are shown in Table 5. A small number of patients
(6) had a second cancer diagnosed during the study; to
avoid confusion, Table 5 lists only the first diagnosis re-
corded. As shown in Table 6, the three most common
indications for corticosteroids were non-specific symp-
toms, neurological symptoms and soft tissue infiltration
which accounted for 80% of all prescribing events. The
most common indication was non-specific, ranging from
33% to 61% of total prescribing events across the six hos-
pices. The difference between hospices for non-specific
prescribing was statistically significant (p = 0.026), but this
has to be interpreted with caution due to possible different
interpretations of non-specific. There were 30 prescribing
events (9.6%) classified as not clear/other.
Dexamethasone was by far the most commonly pre-
scribed agent (72.7% of all prescribing events) and both
the oral and parenteral routes were used. It was the only
medicine to be prescribed for all eight indications. Pred-
nisone and methylprednisolone were prescribed in 21.5%
and 5.8% of instances respectively. The two indications
with the highest proportion of dexamethasone prescrib-
ing were non-specific and neurological symptoms (29.9%
and 31.6% of dexamethasone events respectively).
Table 7 illustrates the dose ranges for the three agents
by indication, including the median starting and final
doses. An attempt was made to determine the cumulative
dose per patient, but this was not possible to accurately
Table 5 Demographic characteristics of sampled patients prescribed corticosteroids
Facility
(Number of patients)
Cancer diagnosis number of patients (%) Gender number of patients (%) Age (Years)
Yes No Male Female Mean (s.d.)
Hospice 1 (70) 66 (94%) 4 (6%) 28 (40%) 42 (60%) 66 (14)
Hospice 2 (50) 50 (100%) 0 (0%) 28 (56%) 22 (44%) 66 (13)
Hospice 3 (40) 36 (90%) 4 (10%) 18 (45%) 22 (55%) 71 (12)
Hospice 4 (24) 21 (87%) 3 (13%) 12 (50%) 12 (50%) 68 (13)
Hospice 5 (31) 31 (100%) 0 (0%) 11 (35%) 20 (65%) 63 (14)
Hospice 6 (45) 44 (98%) 1 (2%) 22 (49%) 23 (51%) 62 (13)
Total (260) 248* (95%) 12 (5%) 119 (46%) 141 (54%) 66 (13)
*A small number of patients (6) had a second cancer diagnosed during the course of the study; only the initial diagnosis is listed in this table.
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median doses of the agents across the six hospices, par-
ticularly for the main indications, while the median dose
varied according to indication in some instances. In the
case of dexamethasone, for example, the median dose was
4 mg for non-specific indications and 8 mg for neuro-
logical indications.
The length of time patients were prescribed corticoste-
roids varied from a single dose prescribed for one day, to
a course continuing for 477 days, with a median duration
for all indications of 29 days (interquartile range (IQR):
20 days) as shown in Table 8. It should be noted that full
information about course duration was available for only
214 of the 312 corticosteroid prescribing episodes (68.5%),
due to difficulty in interpretation of records or lack of
recording in the notes. A separate analysis of this data
showed that 119 of 212 patients (56.1%) received a cor-
ticosteroid course for longer than three weeks (at which
time some degree of adrenal suppression might be antici-
pated). Data were collected on the manner in which
corticosteroids were stopped, that is whether they were re-
duced gradually, stopped abruptly, or the patient died
while on a course of corticosteroids. Seventy-two of 310Table 6 Corticosteroid prescribing events by indication in







1. Non-specific 126 (40.4%) 34.6% – 46.1%
2. Neurological: 79 (25.3%) 20.3% – 30.3%
3. Capsular stretching 14 (4.5%) 2.2% – 6.8%
4. Soft tissue infiltration 45 (14.4%) 10.4% – 18.4%
5. Tenesmus 3 (1.0%) 0.0% – 2.0%
6. Inflammation with syringe
driver sites
10 (3.2%) 1.3% – 5.1%
7. Not clear/other 30 (9.6%) 6.2% – 13.0%
8. Chemotherapy 5 (1.6%) 0.0% – 3.2%
Total 312* (100%)
*There were 312 separate corticosteroid prescribing events documented in the
case notes of the 260 patients reviewed.courses were stopped abruptly (23.2%) and a cortico-
steroid had been prescribed for longer than three weeks
in 35 of these cases (49%). Table 9 lists the reasons for
abrupt stopping; it is notable that in nearly half of the
documented instances (45.8%), the patient was unable
to swallow.
The proportion of patients with adverse effects to cor-
ticosteroids recorded in their notes ranged from 15% to
45% across the six hospices.. It is highly likely that more
patients experienced adverse effects than were recorded.
A significant difference in recording between the hos-
pices was found (p = 0.0001). While the lack of recording
is a notable finding in itself, it is not possible to draw
useful conclusions about the true incidence of adverse
effects from this data.
Table 10 illustrates that documented reviews of cor-
ticosteroid prescribing varied considerably between the
hospices with percentages ranging from 28% to 66% with
a mean (s.d.) of 52% (13.1%). Guidelines were evident in
only one hospice (Hospice 3). Each patient in this hospice
had a separate corticosteroid sheet on which the reducing
corticosteroid regimen was written. The medication chart,
when referring to the corticosteroid, stated ‘as per proto-
col’. As there were often several tapering schedules on
separate forms for the same patient running concurrently,
sometimes with contradictory information, this data was
difficult to interpret retrospectively. The recorded reviews
in the notes are probably an underestimate of actual re-
views at this hospice.
Discussion
While there have been a number of reports of cortico-
steroid prescribing practices in the palliative care setting
internationally, this retrospective review of corticosteroid
prescribing across six hospices is, to our knowledge, the
first of its kind in New Zealand. It also appears to be
one of only a few multi-site retrospective analyses to be
reported and is possibly the largest of its kind to date. It
mostly confirms previous literature findings, as well as
raising some specific issues, such as abrupt stopping, for
further debate.













Pred (59) 20 (20) 5 - 60 20 (20)
Meth (3) 125 (0) 125 - 125 125 (0)
Dex (67) 4 (4) 1 - 8 4 (4)
2. Neurological
Pred (0) - - -
Meth (6) 125 (0) 80 - 125 125 (0)
Dex (71) 8 (8) 2 - 16 8 (8)
3. Capsular stretching
Pred (1) 20 (0) 20 - 20 20 (0)
Meth (0) - - -
Dex (12) 8 (4) 4 - 12 8 (4)
4. Soft tissue
infiltration
Pred (1) 20 (0) 20 - 20 20 (0)
Meth (7) 125 (0) 125 - 125 125 (0)
Dex (32) 8 (4) 4 - 16 8 (4)
5. Tenesmus
Pred (0) - - -
Meth (0) - - -
Dex (2) 8 (0) 8 - 8 8 (0)
6. Inflammation
s/c sites
Pred (0) - - -
Meth (0) - - -
Dex (10) 0.75 (0.5) 0.5 - 1 1 (0.5)
7. Not clear/other
Pred (3) 10 (0) 6 - 80 10 (0)
Meth (1) 1000** (0) 1000 - 1000** 1000** (0)
Dex (24) 8 (4) 1 - 32 4 (4)
8. Chemotherapy
Pred (2) 15(0) 10 - 20 15 (0)
Meth (1) 125 (0) 125 - 125 125 (0)
Dex (6) 12 (8) 4 - 16 8 (6)
Total*
Pred (66, 21.5%) 20 (20) 5 - 80 20 (20)
Meth (18, 5.8%) 125 (0) 80 - 1000** 125 (0)
Dex (224, 72.7%) 8 (4) 1 - 40 8 (4)
Key: IQR: Interquartile range; Pred: prednisone; Meth: methylprednisolone;
Dex: dexamethasone.
*308 of 312 corticosteroid prescribing events are reported (four missing sets
of data).
**There was a single instance of methylprednisolone being prescribed at a
dose of 1000 mg; the reason for this dose was not recorded in the notes.
Table 8 Duration of corticosteroid course by indication
Indication (Number of
prescribing events)
Duration of course (days)
Minimum Maximum Median (IQR)
1. Non-specific (83) 1 432 28 (22)
2. Neurological (64) 2 477 34 (18)
3. Capsular stretching (9) 2 312 18 (23)
4. Soft tissue infiltration (39) 2 101 14 (10)
5. Tenesmus (2) 4 7 5.5 (0)
6. Inflammation s/c sites (1) 1 1 1 (0)
7. Not clear/other (16) 3 172 7 (6)
8. Chemotherapy (0) - - -
Total (214)* 1 477 29 (20)
Key: IQR: Interquartile range.
*The full duration of the corticosteroid course was able to be determined for
214 of the 312 corticosteroid prescribing events.
Table 9 Reasons for stopping corticosteroid abruptly
Reason for stopping corticosteroid
abruptly
Number of events (%)
1. Patient not swallowing 33 (45.8%)
2. Patient stopped their own corticosteroid 4 (5.6%)
3. Gastric bleed 2 (2.8%)
4. Documented adverse effects 3 (4.2%)
5. Switched to bolus dose or short course 6 (8.3%)
6. Reason not documented 24 (33.3%)
Total 72* (100%)
*72 of 310 corticosteroid prescribing events (23.2%) were recorded as
‘stopped abruptly’.
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in this study (65%) was consistent with previous literature
(4,6,8,14.28,34,35,39-42), and there was little variationbetween the hospices (range 61 – 69%) which suggests
that this is an accurate reflection of prescribing practice
throughout New Zealand. The most frequent prescribing
indication was non-specific (40.4%), again this is in line
with international experience if a broad definition of non-
specific is used [4,14]. While this is a notable result, given
that there is relatively little published evidence to support
the use of corticosteroids for non-specific reasons [48], it
has to be interpreted with some caution because of vary-
ing definitions of non-specific indications in the literature.
In addition, a recent randomised controlled trial of dexa-
methasone 8 mg daily has demonstrated significant reduc-
tions in cancer-related fatigue in patients with advanced
cancer, providing good evidence for its use in this non-
specific indication [49]. Neurological (25.3%) and soft
tissue infiltration (14.4%) were the most frequent spe-
cific indications; this finding is supported by two UK
studies [40,43].
The only corticosteroid prescribed for all indications
was dexamethasone (72.7% of prescribing events), with
less prescribing of prednisone (21.5%) and methylpred-
nisolone (5.8%). Dexamethasone is currently the most
Table 10 Documented corticosteroid reviews
Facility (Number of patients) Number of reviews documented (%)
Hospice 1 (70) 46 (65.7%)
Hospice 2 (50) 28 (56%)
Hospice 3 (40)* 11* (27.5%)
Hospice 4 (24) 11 (45.8%)
Hospice 5 (31) 14 (45.2%)
Hospice 6 (45) 25 (55.5%)
Total (260) 135 mean (s.d.): 52% (13.1%)
*Hospice 3 used a separate corticosteroid dosing sheet on which the reducing
regimen was written; as a consequence, a smaller percentage of reviews were
documented in the notes.
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33-38], principally because it has the greatest anti-
inflammatory effect and the longest biological half-life
[24]. Whilst corticosteroid guidelines were only evident
in one of the sample hospices studied, it was reassuring
to discover that, without guidelines, the median dose for
the most common indications were similar. This was
contrary to Shafford’s [14] study that suggested there
was a divergence of dose ranges even in the presence of
guidelines [13]. However, prescribers in the current
study seldom used the same course duration or rate of
reduction of dose. It is interesting to speculate as to
whether guidelines are required in the New Zealand
context, given the notable consistency in the proportion
of patients receiving corticosteroids and in the doses used
for different indications. Conversely, the wide variation in
dose reduction or stopping, supports guideline develop-
ment and use.
A number of researchers suggest that corticosteroids
can be stopped abruptly if they have been prescribed for
less than three weeks [50], but should be titrated down
after this period. In this study, 72 (23.2%) patients had
their corticosteroids stopped suddenly and 35 of these
(49%) had been on the agent longer than three weeks,
including those whose medicines were stopped when
they could no longer swallow. Some literature suggests
that stopping long-term corticosteroid therapy abruptly
is unethical and may lead to an adrenal crisis, restless-
ness, anxiety and hasten death [25,43,45-47]. Although
stopping long-term therapy if the patient is no longer
swallowing appears to be common practice, it is both
clinically and ethically questionable and merits further
debate, particularly as parenteral formulations of these
medicines are available and a route change is possible.
In the sample hospices, monitoring and review could
not be assumed to have taken place if it had not been re-
corded in the patient notes. It was not clear if this was a
case of reviews and monitoring being conducted and not
recorded, or not occurring at all. Lack of recording of ad-
verse effects of corticosteroids in patient notes wasevident. These effects appeared to be under-reported (15%
to 45% across the hospices). These findings are supported
by a 2008 nationwide survey in Japan where a low per-
centage of adverse effects was also reported [6], yet a
number of authors suggest that 50% to 75% of patients
prescribed corticosteroids for more than three weeks will
have adverse effects [3,4,14].
There were a number of limitations to the current study.
The study sample was restricted to New Zealand, so
generalizability of findings internationally may be limited.
Nevertheless, the findings generally mirrored overseas
experience as reported in the literature. The ‘snapshot’ of
corticosteroid prescribing was for the 2007 calendar year
and there may have been practice changes, such as the
introduction of guidelines, since that time. As the review
was retrospective and all patients had died by the time
data was collected (2009), it was not possible to follow-up
patients to corroborate findings.
Accessing and interpreting case notes were often chal-
lenging and each hospice had a different approach to
where and how prescribing information was recorded.
As the only information available to the researchers was
inpatient notes and associated documentation such as
drug charts and correspondence, it is reasonable to specu-
late whether differences in the individual hospices were
due to actual prescribing or to recording practices. The
authors made every attempt to minimise the impact of dif-
ferent recording practices (the majority of records were
handwritten).
Some data was very difficult to retrieve or interpret
using the retrospective analysis of case notes. For example,
it was not possible to determine cumulative corticosteroid
doses for the majority of events, nor was it possible to
accurately track dose or route changes, particularly for ta-
pering regimens. Additionally, it is highly likely that re-
views and adverse effects are underestimated in this study,
because of non-recording. Given the above described limi-
tations of a retrospective design it would be useful to
conduct a prospective study in actual hospice settings.
Notwithstanding these limitations, the study has provided
some useful insights into the prescribing of corticosteroids
in the context of palliative care.
Conclusion
The proportion of New Zealand palliative patients pre-
scribed corticosteroids was in line with international lit-
erature, but there was a notable consistency between
hospices in this study. Most commonly, corticosteroids
were prescribed for non-specific reasons and the agent
of choice was dexamethasone. Dose ranges and course
durations largely mirrored international experience.
Only one hospice used guidelines and most prescribing
appeared to be prescriber-driven. The reduction and
stopping of corticosteroids appeared to be ad hoc even
Denton and Shaw BMC Palliative Care 2014, 13:7 Page 8 of 9
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documentation and recording of review and monitoring
of these drugs and their adverse effects. These findings
are generally consistent with the international literature
in this area and this study adds weight to the need for
ongoing discussion about the role of these drugs in
palliative care.
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